Report LibraryAll Reports
Datamonitor Healthcare CV&Met Disease Analysis: Non-Alcoholic Steatohepatitis (NASH)
October 14, 2020
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of patients who have fatty liver in the absence of significant alcohol consumption. NAFLD patients are often segmented into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) patients. NAFLD diagnosis requires evidence of hepatic steatosis and lack of secondary causes of liver fat accumulation such as substantial alcohol consumption, long-term use of a steatogenic medicine, or monogenic hereditary disorders. NASH is defined as the presence of >5% hepatic steatosis and inflammation with hepatocyte injury, with or without fibrosis. Although the presence of fibrosis is not required for a diagnosis of NASH, fibrosis is present in over 80% of NASH patients. For this reason, NASH patients are often further segmented by their fibrosis stage.
NASH represents a great clinical burden due to the high liver-related and non-liver-related mortality rates associated with the disease. Moreover, advanced NASH patients are at increased risk of developing cirrhosis, which is linked to liver decompensation, end-stage liver disease, and hepatocellular carcinoma. Consequently, NASH is set to become the most common indication for liver transplant in the US, which creates a significant economic burden on healthcare systems, therefore augmenting the urgency to find an efficacious therapy.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Non-Alcoholic Steatohepatitis (NASH)|